OKYO Pharma Ltd

OKYO Pharma’s insider buy‑in and OIS XV presentation boost confidence in its pre‑clinical eye‑pain drug, urcosimod, highlighting a niche high‑growth biotech opportunity.

OKYO Pharma’s investigational drug urcosimod has received FDA Fast Track designation for treating neuropathic corneal pain, a chronic and severe ocular condition with no FDA-approved therapy.